REDWOOD CITY, Calif.--(EON: Enhanced Online News)--Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today positive preclinical findings generated using the Company’s Immune Repertoire Capture® (IRC™) technology, presented at the IBC Antibody Engineering & Therapeutics Conference being held in San Diego, California, December 11-15, 2016. In a presentation entitled “Analyzing B-cell Receptor Repertoires from Human Studies,” Daniel Emerling, Ph.D., Atreca’s Senior Vice President, Research, provided a summary of key findings from the Company’s preclinical programs, including:
“We will continue to advance multiple programs through preclinical studies to the clinic, with a primary focus on cancer immunotherapy applications of our novel and proprietary IRC™ platform.”
- Atreca’s IRC™ technology has identified and generated antibodies from active human immune responses, including antibodies from cancer patients who have responded well to immunotherapy and other treatments, patients with autoimmune disease, vaccinated subjects, and patients with infections.
- Atreca’s immuno-oncology program is advancing antibodies that selectively bind tumor tissue types beyond that of the original patient and display potent anti-tumor activity in vivo.
Dr. Emerling stated, “Atreca’s IRC™ platform has demonstrated in preclinical disease models the power of mining a patient’s own anti-tumor immunity. In one of our applications of IRC™, we generate natively paired antibody heavy and light chain sequences from blood plasmablasts – activated B cells – that are critical to the body’s own immune response to cancer and pathogens. As our programs progress, we anticipate being able to advance these promising biologic agents for potential use in cancer immunotherapy, vaccines, and diverse additional therapeutic applications.”
“Over the past year, Atreca has made substantial progress both in advancing our internal and partnered programs and attracting world-class experts to our leadership team and advisory group,” said Tito A. Serafini, Ph.D., Atreca’s President, Chief Executive Officer, and Co-Founder. “We will continue to advance multiple programs through preclinical studies to the clinic, with a primary focus on cancer immunotherapy applications of our novel and proprietary IRC™ platform.”
More information on the Antibody Engineering & Therapeutics Conference is available at: https://lifesciences.knect365.com/antibody-engineering-therapeutics/.
About Atreca, Inc.
Atreca is a privately held biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atreca’s proprietary Immune Repertoire Capture® technology profiles a patient’s immune response at the single-cell level at very high throughput without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates with the objective of enhancing engagement of the human immune response in cancer treatment and other indications, thus optimizing therapeutic outcomes. For more information on Atreca, please visit www.atreca.com.